Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and twelve have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $34.6364.

Several equities research analysts recently commented on the company. Truist Financial boosted their price target on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Immunome in a research note on Thursday, September 10th. Wedbush lifted their target price on shares of Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

Insider Activity at Immunome

In other Immunome news, insider Jack Higgins sold 13,200 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider directly owned 65,050 shares of the company’s stock, valued at $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the transaction, the director owned 92,211 shares in the company, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 635,510 shares of company stock valued at $14,915,990. Insiders own 7.21% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IMNM. Integrated Wealth Concepts LLC bought a new position in shares of Immunome in the 2nd quarter valued at approximately $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Immunome during the second quarter worth approximately $576,000. Readystate Asset Management LP boosted its position in Immunome by 23.3% during the second quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock worth $34,027,000 after purchasing an additional 303,958 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in Immunome during the second quarter valued at approximately $552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Immunome by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after purchasing an additional 1,625 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Up 0.2%

Shares of NASDAQ:IMNM opened at $23.97 on Friday. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -9.47 and a beta of 2.13. Immunome has a 1 year low of $9.27 and a 1 year high of $30.06. The business has a fifty day simple moving average of $25.33 and a 200 day simple moving average of $22.78.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, sell-side analysts forecast that Immunome will post -2.38 EPS for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.